The road towards product development and regulatory approval is long, arduous and costly. Thus, to recoup the money invested in the drug and make it profitable, manufacturers are combining drugs to make fixed dose combinations and entering them into the NDA list, thus giving them huge profit and demand. Balamuralidhara V, Raghunandan H.V. and Suresha M. at JSS College of
Pharmacy argue that this leads to long-term presence of the product in the market at the cost of the health and safety of patients.